South Africa’s Breakthrough: Lenacapavir Rollout for HIV Prevention ### DATELINE: Johannesburg, South Africa – June 26, 2026 In a groundbreaking move to combat the HIV/AIDS epidemic, South Africa is set to introduce lenacapavir, a long-acting and highly effective HIV prevention injection, marking a new era in the nation’s HIV prevention efforts.
The South African National AIDS Council (SANAC) and the National Department of Health, in collaboration with UNAIDS, have initiated the rollout of this innovative medicine, which is expected to support the country’s ambitious goal of reducing and ultimately preventing new HIV infections. ### NUT GRAF: The introduction of lenacapavir, a twice-yearly injectable pre-exposure prophylaxis (PrEP), represents a significant shift in HIV prevention strategies.
South Africa’s commitment to expanding access to effective prevention options has been further demonstrated through this initiative, which is lauded by the World Health Organization (WHO) for its leadership in advancing HIV prevention.
### BODY: South Africa, addressing a significant HIV/AIDS burden, has approximately 8. 15 million people living with HIV, accounting for about 12.
9% of the total population as of 2025.
The country has been at the forefront of the global HIV response, implementing various strategies to combat the disease.
The introduction of lenacapavir is a testament to South Africa’s ongoing dedication to addressing the HIV/AIDS crisis.
This groundbreaking long — acting injection provides a significant advantage over daily oral regimens, which often face adherence difficulties.
The South African Government News Agency and the Daily Maverick have highlighted the potential of lenacapavir to mark a new era in HIV prevention efforts.
However, the rollout of lenacapavir is not without its challenges.
The suspension of foreign aid, particularly from the United States’PEPFAR program, which had been crucial for the country’s HIV/AIDS program, poses significant challenges.
The South African News Agency (SANews) has reported on the efforts to find solutions to ensure the continuity of the life-saving HIV and AIDS program.
The World Health Organization (WHO) has applauded South Africa’s leadership in advancing HIV prevention through the rollout of lenacapavir.
The WHO Director — General, Dr. Tedros Adhanom Ghebreyesus, commended the government and people of South Africa on the rollout of the national lenacapavir program, emphasizing the country’s commitment to expanding access to effective prevention options.
The introduction of lenacapavir in South Africa is not only a significant milestone in the country’s efforts to reduce new HIV infections but also a testament to the nation’s role as a global leader in the HIV response.
As South Africa continues to face challenges in its HIV/AIDS program, the rollout of lenacapavir represents a beacon of hope and a commitment to the health and well-being of its citizens. ### KICKER: The successful rollout of lenacapavir in South Africa underscores the nation’s commitment to combating the HIV/AIDS epidemic.
As the country continues to face challenges, the introduction of this innovative medicine is a significant step towards achieving the goal of reducing and ultimately preventing new HIV infections.
South Africa’s leadership in HIV prevention efforts will undoubtedly inspire other nations in their fight against the disease.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: Google News v2
